Genetic association, mutation screening and functional analysis of a kozak sequence variant in the metabotropic glutamate receptor 3 gene in bipolar disorder

JAMA Psychiatry

Volumn 70, Issue 6, 2013, Pages 591-598

  Kandaswamy, Radhika ^a   McQuillin, Andrew ^a   Sharp, Sally I ^a   Fiorentino, Alessia ^a   Anjorin, Adebayo ^a   Blizard, Robert A ^a   Curtis, David ^b   Gurling, Hugh M D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; METABOTROPIC RECEPTOR 3; TRANSCRIPTION FACTOR;

ARTICLE; BINDING SITE; BIOINFORMATICS; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; EXON; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEIN BINDING; RNA TRANSLATION; START CODON;

EID: 84878630996     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.38     Document Type: Article

References (54)

1. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;75(3):889-907. (Pubitemid 30660476)
2. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev. 1999;29(1):83-120. (Pubitemid 29016081)
3. Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):279-283.
4. Ferreira MA, O'Donovan MC, Meng YA, et al Wellcome Trust Case Control Consortium. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40(9):1056-1058.
5. Sklar P, Smoller JW, Fan J, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008;13(6):558-569. (Pubitemid 351704939)
6. Sklar P, Ripke S, Scott LJ, et al Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011;43(10):977-983.
7. Fallin MD, Lasseter VK, Avramopoulos D, et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet. 2005;77(6):918-936. (Pubitemid 41698514)
8. Dalvie S, Horn N, Nossek C, van der Merwe L, Stein DJ, Ramesar R. Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype. Afr J Psychiatry (Johannesbg). 2010;13(4):297-301.
9. Martí SB, Cichon S, Propping P, Nöthen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet . 2002;114(1):46-50.
10. Tsunoka T, Kishi T, Ikeda M, et al. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):875-879.
11. Sartorius LJ, Nagappan G, Lipska BK, et al. Alternative splicing of human metabotropic glutamate receptor 3. J Neurochem. 2006;96(4):1139-1148.
12. Corti C, Xuereb JH, Corsi M, Ferraguti F. Identification and characterization of the promoter region of the GRM3 gene. Biochem Biophys Res Commun. 2001;286(2):381-387. (Pubitemid 32924925)
13. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008;33(7):1603-1610. (Pubitemid 351684700)
14. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007;13(9):1102-1107. (Pubitemid 47517511)
15. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress. 2003;6(3):189-197. (Pubitemid 37210425)
16. Spitzer R, Endicott J. The Schedule for Affective Disorders and Schizophrenia, Lifetime Version. 3rd ed. New York: New York State Psychiatric Institute; 1977.
17. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782. (Pubitemid 9064061)
18. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764-770.
19. Pereira AC, McQuillin A, Puri V, et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2011;156(2):177-187.
20. Staden R. The Staden sequence analysis package. Mol Biotechnol. 1996;5(3):233-241. (Pubitemid 126441504)
21. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
22. Fairbrother WG, Yeh RF, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. Science. 2002;297(5583):1007-1013. (Pubitemid 34856033)
23. Grillo G, Turi A, Licciulli F, et al. UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res. 2010;38(database issue):D75-D80.
24. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31(13):3406-3415. (Pubitemid 37442169)
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265. (Pubitemid 40202029)
26. Curtis D, Vine AE, Knight J. A simple method for assessing the strength of evidence for association at the level of the whole gene. Adv Appl Bioinform Chem. 2008;1:115-120.
27. Datta SR, McQuillin A, Rizig M, et al. A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia. Mol Psychiatry. 2010;15(6):615-628.
28. Berardi P, Meyyappan M, Riabowol KT. A novel transcriptional inhibitory element differentially regulates the cyclin D1 gene in senescent cells. J Biol Chem. 2003;278(9):7510-7519. (Pubitemid 36800758)
29. Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5 ' UTR of the gene. Thyroid. 2006;16(7):625-632.
30. Minet E, Ernest I, Michel G, et al. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5'UTR. Biochem Biophys Res Commun. 1999;261(2):534-540. (Pubitemid 29392511)
31. Singh IS, He JR, Calderwood S, Hasday JD. A high affinity HSF-1 binding site in the 5'-untranslated region of the murine tumor necrosis factor-alpha gene is a transcriptional repressor. J Biol Chem. 2002;277(7):4981-4988. (Pubitemid 34968537)
32. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene. 1999;234(2):187-208. (Pubitemid 29298181)
33. Bisio A, Nasti S, Jordan JJ, et al. Functional analysis of CDKN2A/p16INK4a 5′-UTR variants predisposing to melanoma. Hum Mol Genet. 2010;19(8):1479-1491.
34. Lukowski SW, Bombieri C, Trezise AE. Disrupted post-transcriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a 5′UTR mutation is associated with a CFTR-related disease. Hum Mutat. 2011;32(10):E2266-E2282. doi:10.1002/humu.21545.
35. Signori E, Bagni C, Papa S, et al. A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene. 2001;20(33):4596-4600. (Pubitemid 32772444)
36. Jacobson EM, Concepcion E, Oashi T, Tomer YA. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology. 2005;146(6):2684-2691. (Pubitemid 40695571)
37. Baker RI, Eikelboom J, Lofthouse E, et al. Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood. 2001;98(1):36-40.
38. Maguire JM, Thakkinstian A, Sturm J, et al. Polymorphisms in platelet glycoprotein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis. Stroke. 2008;39(6):1710-1716.
39. Ozturk A, DeKosky ST, Kamboh MI. Genetic variation in the choline acetyltransferase (CHAT) gene may be associated with the risk of Alzheimer's disease. Neurobiol Aging. 2006;27(10):1440-1444.
40. Osgood D, Corella D, Demissie S, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the Framingham study. J Clin Endocrinol Metab. 2003;88(6):2869-2879. (Pubitemid 36724469)
41. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence [published corrections appear in Mol Psychiatry. 2005;10(8):804 and Mol Psychiatry. 2005;10(4):420]. Mol Psychiatry. 2005;10(1):40-68. (Pubitemid 40139588)
42. Mössner R, Schuhmacher A, Schulze-Rauschenbach S, et al. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur Neuropsychopharmacol. 2008;18(10):768-772.
43. Straub RE, Weinberger DR. Schizophrenia genes - famine to feast. Biol Psychiatry. 2006;60(2):81-83.
44. Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry. 2007;62(7):747-755. (Pubitemid 47374649)
45. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology. 2008;33(11):2626-2634.
46. Kozak M. How do eucaryotic ribosomes select initiation regions in messenger RNA? Cell. 1978;15(4):1109-1123. (Pubitemid 9109673)
47. Spooren WP, Gasparini F, Salt TE, Kuhn R. Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders. Trends Pharmacol Sci . 2001;22(7):331-337. (Pubitemid 32592465)
48. Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl). 2005;179(1):284-291. (Pubitemid 40576716)
49. Wierońska JM, Legutko B, Dudys D, Pilc A. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol Rep. 2008;60(6):844-855.
50. Matrisciano F, Caruso A, Orlando R, et al. Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology. 2008;55(4):525-531.
51. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse. 2005;57(3):123-131. (Pubitemid 41023469)
52. González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452(7183):93-97. (Pubitemid 351355090)
53. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: amechanism for antipsychotic drug action? Am J Psychiatry. 2009;166(7):812-820.
54. Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004;46(4):457-467. (Pubitemid 38224431)